Posts

Pelacarsen’s trial miss clouds the future of Lp(a) cholesterol drugs

on

Bayer says it is working on a U.S. MFN pricing agreement

on

FDA grants uniQure’s Huntington’s gene therapy Priority Review

on

Pfizer beats Q3 estimates and raises 2026 outlook

on

Novartis ends BioArctic neuroscience deal worth up to $802 million

on

Midstream Health raises $20 million to improve hospital finances

on

CinRx and Graviton form CinRock to pursue ROCK2 therapies for heart and lung conditions

on

FDA partial hold on Bright Minds’ BMB-101 trial sends shares sharply lower

on

Karyopharm’s proposed Ayrmid deal is part of a Chapter 11 restructuring

on

Merck to sell U.S. CDMO business to Lonza

on

InventisBio reports Phase III psoriasis win for nomelcitinib

on

Eos reports preliminary PTC-2105 results in aged rats

on

Tiziana reports mixed-positive Phase 2a results for intranasal foralumab

on